No annual revenue total was found in Erasca, Inc.'s SEC filings.
Erasca, Inc. (ERAS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$95.6 million. As of Jun 30, 2026 it held $384.3 million in cash and investments and $44.7 million in total debt.
Revenue
—
Net income (TTM)
$-287.22M
-123.9% vs year-ago TTM
Operating cash flow (TTM)
$-98.02M
+1.1% vs year-ago TTM
Free cash flow (TTM)
$-98.08M
+1.1% vs year-ago TTM
EPS (TTM)
$-0.97
-114.2% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
310.80M
+9.7% vs prior year
Net cash
$339.56M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERAS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1761918
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M |
| Diluted EPS | -$0.44 | -$0.69 | -$0.83 | -$1.99 | — |
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M |
| Free cash flow | -$95.6M | -$109.5M | -$103.0M | -$117.8M | -$90.8M |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M |
| Stockholders' equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M |
| Cash and investments | $341.8M | $440.5M | $322.0M | $435.6M | $459.2M |
| Total debt | $47.1M | $51.9M | $55.9M | $55.1M | $18.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 13, 2026 |
All 352 Erasca, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.